299 related articles for article (PubMed ID: 3968450)
61. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
[TBL] [Abstract][Full Text] [Related]
62. Immunoglobulins in bile and serum of the rabbit associated with protection after Vibrio cholerae infection and vaccination.
Rijpkema SG; Jansen WH; Gielen H; Guinée PA
Microb Pathog; 1987 Nov; 3(5):365-75. PubMed ID: 2462153
[TBL] [Abstract][Full Text] [Related]
63. Antitoxic immunity to cholera in dogs immunized orally with cholera toxin.
Pierce NF; Cray WC; Engel PF
Infect Immun; 1980 Feb; 27(2):632-7. PubMed ID: 7380543
[TBL] [Abstract][Full Text] [Related]
64. Experimental studies on cholera immunization. 4. The antibody response to formalinized Vibrio cholerae and purified endotoxin with special reference to protective capacity.
Svennerholm AM
Int Arch Allergy Appl Immunol; 1975; 49(4):434-52. PubMed ID: 808500
[TBL] [Abstract][Full Text] [Related]
65. Serologic differentiation between antitoxin responses to infection with Vibrio cholerae and enterotoxin-producing Escherichia coli.
Svennerholm AM; Holmgren J; Black R; Levine M; Merson M
J Infect Dis; 1983 Mar; 147(3):514-22. PubMed ID: 6339647
[TBL] [Abstract][Full Text] [Related]
66. Oral immunization of dogs with purified cholera toxin, crude cholera toxin, or B subunit: evidence for synergistic protection by antitoxic and antibacterial mechanisms.
Pierce NF; Cray WC; Sacci JB
Infect Immun; 1982 Aug; 37(2):687-94. PubMed ID: 6889574
[TBL] [Abstract][Full Text] [Related]
67. Evaluation of TcpF-A2-CTB chimera and evidence of additive protective efficacy of immunizing with TcpF and CTB in the suckling mouse model of cholera.
Price GA; Holmes RK
PLoS One; 2012; 7(8):e42434. PubMed ID: 22879984
[TBL] [Abstract][Full Text] [Related]
68. [Seroepidemiological survey of El Tor cholera in an endemic region of Algeria].
Bendib A; Nora M; Mahrouf H; Saib M; el Abassi K; Dodin A
Bull Soc Pathol Exot; 1994; 87(3):143-7. PubMed ID: 7827512
[TBL] [Abstract][Full Text] [Related]
69. Evidence that inactivated oral cholera vaccines both prevent and mitigate Vibrio cholerae O1 infections in a cholera-endemic area.
Clemens JD; Sack DA; Rao MR; Chakraborty J; Khan MR; Kay B; Ahmed F; Banik AK; van Loon FP; Yunus M
J Infect Dis; 1992 Nov; 166(5):1029-34. PubMed ID: 1402014
[TBL] [Abstract][Full Text] [Related]
70. Specific antibodies to cholera toxin in rabbit milk are protective against Vibrio cholerae-induced intestinal secretion.
Yoshiyama Y; Brown WR
Immunology; 1987 Aug; 61(4):543-7. PubMed ID: 3443455
[TBL] [Abstract][Full Text] [Related]
71. Immune responses following killed whole vibrio-B subunit oral cholera vaccine in human volunteers.
Pitisuttithum P; Migasena S; Suntharasamai P; Supanaranond W; Desakorn V; Prayurahong B
Southeast Asian J Trop Med Public Health; 1989 Jun; 20(2):201-5. PubMed ID: 2609209
[TBL] [Abstract][Full Text] [Related]
72. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
[TBL] [Abstract][Full Text] [Related]
73. [Value of vibriocidal antibody research in endemic areas of Vibrio cholerae 0:1].
Bendib A; Bougoudogo F; Messast M; Rezkallah D; Hamchi L; Bellouche Y; Aidoud NS; Keddouri A; Fournier JM; Dodin A
Bull Soc Pathol Exot; 1994; 87(1):33-7. PubMed ID: 8003902
[TBL] [Abstract][Full Text] [Related]
74. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
[TBL] [Abstract][Full Text] [Related]
75. Duration of infection-derived immunity to cholera.
Levine MM; Black RE; Clements ML; Cisneros L; Nalin DR; Young CR
J Infect Dis; 1981 Jun; 143(6):818-20. PubMed ID: 7252264
[TBL] [Abstract][Full Text] [Related]
76. Plasma Leptin Levels in Children Hospitalized with Cholera in Bangladesh.
Falkard B; Uddin T; Rahman MA; Franke MF; Aktar A; Uddin MI; Bhuiyan TR; Leung DT; Charles RC; Larocque RC; Harris JB; Calderwood SB; Qadri F; Ryan ET
Am J Trop Med Hyg; 2015 Aug; 93(2):244-249. PubMed ID: 26055740
[TBL] [Abstract][Full Text] [Related]
77. Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.
Kundu J; Mazumder R; Srivastava R; Srivastava BS
FEMS Immunol Med Microbiol; 2009 Jul; 56(2):179-84. PubMed ID: 19453752
[TBL] [Abstract][Full Text] [Related]
78. Brucella antibodies and oral cholera vaccination.
Begue RE; Guillen A; Meza R
Lancet; 1995 Jul; 346(8967):115-6. PubMed ID: 7603186
[No Abstract] [Full Text] [Related]
79. The pathogenicity of nonenterotoxigenic Vibrio cholerae serogroup O1 biotype El Tor isolated from sewage water in Brazil.
Levine MM; Black RE; Clements ML; Cisneros L; Saah A; Nalin DR; Gill DM; Craig JP; Young CR; Ristaino P
J Infect Dis; 1982 Mar; 145(3):296-9. PubMed ID: 7061878
[TBL] [Abstract][Full Text] [Related]
80. Biotype as determinant of natural immunising effect of cholera.
Clemens JD; van Loon F; Sack DA; Rao MR; Ahmed F; ChakrabortY J; Kay BA; Khan MR; Yunus MD; Harris JR
Lancet; 1991 Apr; 337(8746):883-4. PubMed ID: 1672971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
